Peak Bio Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of commercialization of therapeutics that aim to address the medical need of patients with inflammatory, rare and specialty diseases, and cancer. It focuses on the development of treatment of alpha-1 antitrypsin (AAT) deficiency (AATD), a genetic disorder that may result in lung disease or liver disease. The company was founded by Ho Young Huh on February 1, 2016 and is headquartered in Pleasanton, CA.